© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to February
mut. BRAF sel. heterobifunctional degrader
efficacy in xenograft at 50 mg/kg IP BID
VHL-based degrader from vemurafenib
Nat. Comm., Feb. 10, 2021
Yale University, New Haven, CT
13. The Yale BRAF-targeting PROTAC SJF-0628 is a VHL-based heterobifunctional degrader with in vivo activity in a xenograft model (50 mg/kg BID IP). Though mutant BRAF is a well-validated…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.